Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023
22 févr. 2024 09h15 HE
|
Sanara MedTech Inc.
FORT WORTH, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical...
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
13 févr. 2024 16h00 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving...
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
26 janv. 2024 08h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences...
NeuroOne® to Report Fourth Quarter and Fiscal Year 2023 Financial Results and Provide Corporate Update on December 14
07 déc. 2023 16h30 HE
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Dec. 07, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing
30 nov. 2023 09h15 HE
|
Sanara MedTech Inc.
FORT WORTH, TX, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical...
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
16 nov. 2023 08h00 HE
|
NeuroOne Medical Technologies Corp
Patent allowance strengthens IP portfolio and positions company in pursuing drug delivery using its neural probes EDEN PRAIRIE, Minn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14 nov. 2023 17h15 HE
|
NeuroOne Medical Technologies Corp
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical...
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
13 nov. 2023 16h14 HE
|
Nemaura Medical, Inc
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a...
Sanara MedTech Inc. Announces Third Quarter 2023 Results
13 nov. 2023 16h05 HE
|
Sanara MedTech Inc.
FORT WORTH, TX, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical...
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
07 nov. 2023 08h00 HE
|
NeuroOne Medical Technologies Corp
Feedback from responses to FDA anticipated in 30 days Commercialization remains on track in first half of 2024 pending FDA clearance Product potential for transformative improvement in...